EirGenix is a contract development and manufacturing organization to provide high quality and cost-effectiveness service supporting our clients in development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing both in mammalian cell and microbial expression systems.
EirGenix provides not just technology services but integral solutions that one can rely on. Their main capability includes cell line development, process development and scale-up, analytical development, biologic characterizations, and cGMP manufacturing.
Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing…
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors…
Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI…
Taiwan’s investment culture remains heavily oriented toward semiconductors and electronics, and few investors are yet convinced to commit capital to biotech Dr. Lin, Founder and Chief Scientific Officer of Tripartite…
A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood…
Contemporary Taiwan finds itself navigating unprecedented healthcare challenges, having transitioned into a super-aged society with unexpected speed, compounded by one of the lowest birth rates globally. In 2024, to secure…
In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort…
Over the past three decades, Taiwan’s elderly population – defined as individuals aged 65 and older – has expanded by a staggering 152 percent. This demographic shift has introduced complex…
Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated…
Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through…
Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At…
Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is…
Access to capital is the difference between life and death for small biotechs and life science start-ups. But in an industry with high levels of failure and decades-long development cycles,…
See our Cookie Privacy Policy Here
